Gastrointestinal effects represent the most frequently reported adverse reactions, occurring in a substantial proportion of patients, particularly during treatment initiation and dose escalation: Nausea (very common, affecting more than 1 in 10 people) typically peaks during the first few weeks and often diminishes with continued treatment [1] [2] Diarrhoea (very common, affecting more than 1 in 10 people) Vomiting (common, affecting up to 1 in 10 people) Abdominal pain, constipation, and dyspepsia occur with variable frequency Reduced appetite is an expected pharmacological effect contributing to weight loss but may occasionally be excessive These gastrointestinal symptoms usually improve over time as the body adjusts to the medication
Research profile GHK-Cu (Copper Peptide) is an educational research profile for people comparing mechanism, potential benefits, evidence strength, and related compounds in anti-aging & longevity
Tirzepatide: The First Dual Agonist Tirzepatide is currently the only FDA-approved dual GIP/GLP-1 receptor agonist
Managing Hemorrhoids While Taking Semaglutide Taking semaglutide can lead to changes in digestion and bowel movements, which may contribute to hemorrhoids or make existing ones worse
The shelf life of prefilled semaglutide injections is 8 weeks (56 days) after opening if stored properly in the refrigerator